Osimertinib remains the frontline therapy for EGFR-mut NSCLC, but 2023 updates revealed that zipalertinib, a fourth-generation inhibitor, achieves a 52% ORR in patients with Ex20ins mutations (NCT04841177). Here, EGFR is linked to non-small cell lung carcinoma.